Novel Biomarkers, ST-Elevation Resolution, and Clinical Outcomes Following Primary Percutaneous Coronary Intervention

Jay S Shavadia1,2, Christopher B Granger1, Wendimagegn Alemayehu2

  • 1Duke Clinical Research Institute Durham NC.

Insights

Suboptimal ST-elevation resolution (ST-ER) after primary percutaneous coronary intervention (PPCI) is linked to platelet activation and NT-proBNP levels. These biomarkers may offer targets for improving microvascular reperfusion in ST-segment-elevation myocardial infarction.

Area of Science:

  • Cardiology
  • Biomarker Discovery
  • Myocardial Infarction Pathophysiology

Background:

  • Microvascular reperfusion after primary percutaneous coronary intervention (PPCI) for ST-segment-elevation myocardial infarction (STEMI) is variable.
  • The underlying pathophysiology of suboptimal ST-elevation resolution (ST-ER) remains unclear despite restored epicardial flow.

Purpose of the Study:

  • To explore associations between pre-PPCI serum biomarkers and ST-ER.
  • To investigate the relationship between biomarkers and 90-day clinical outcomes in STEMI patients.
  • To elucidate the pathophysiology of microvascular reperfusion in STEMI.

Main Methods:

  • Principal component analyses of 91 serum biomarkers clustered into 14 pathobiologic processes.
  • Comparison of ST-ER ≥50% versus <50% groups.
  • Network analyses to understand interbiomarker relationships.
  • Assessment of 90-day composite of death, shock, and heart failure.

Main Results:

  • Suboptimal ST-ER (<50%) was associated with higher pre-PPCI levels of platelet activation markers and NT-proBNP, independent of TIMI grade 3 flow.
  • Strong interbiomarker correlations were observed between myocardial stretch, platelet activation, and inflammation pathways.
  • NT-proBNP was the only biomarker cluster significantly associated with 90-day adverse clinical outcomes.

Conclusions:

  • Suboptimal ST-ER is common in STEMI patients despite successful epicardial reperfusion.
  • Platelet activation markers and NT-proBNP are strongly correlated with suboptimal ST-ER.
  • NT-proBNP independently predicts adverse 90-day outcomes, suggesting it as a potential therapeutic target for enhancing microvascular reperfusion.

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
131
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
282
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
538
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
680
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
425
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
153